Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

The specialised, focused library is developed on demand with the most recent virtual screening and parameter assessment technology, guided by the Receptor.AI drug discovery platform. This approach exceeds the capabilities of traditional methods and offers compounds with higher activity, selectivity, and safety.


The compounds are cherry-picked from the vast virtual chemical space of over 60B molecules. The synthesis and delivery of compounds is facilitated by Reaxense.


The library includes a list of the most effective modulators, each annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Furthermore, each compound is shown with its optimal docking poses, affinity scores, and activity scores, offering a detailed summary.


Our top-notch dedicated system is used to design specialised libraries.


 

Fig. 1. The screening workflow of Receptor.AI

Our methodology employs molecular simulations to explore a wide array of proteins, capturing their dynamic states both individually and within complexes. Through ensemble virtual screening, we address conformational mobility, uncovering binding sites within functional regions and remote allosteric locations. This thorough exploration ensures no potential mechanism of action is overlooked, aiming to discover novel therapeutic targets and lead compounds across an extensive spectrum of biological functions.


Our library stands out due to several important features:


  • The Receptor.AI platform compiles comprehensive data on the target protein, encompassing previous experiments, literature, known ligands, structural details, and more, leading to a higher chance of selecting the most relevant compounds.

  • Advanced molecular simulations on the platform help pinpoint potential binding sites, making the compounds in our focused library ideal for finding allosteric inhibitors and targeting cryptic pockets.

  • Receptor.AI boasts over 50 tailor-made AI models, rigorously tested and proven in various drug discovery projects and research initiatives. They are crafted for efficacy, dependability, and precision, all of which are key in creating our focused libraries.

  • Beyond creating focused libraries, Receptor.AI offers comprehensive services and complete solutions throughout the preclinical drug discovery phase. Our success-based pricing model minimises risk and maximises the mutual benefits of the project's success.


PARTNER
Receptor.AI
 
UPACC
O00159

UPID:
MYO1C_HUMAN

ALTERNATIVE NAMES:
Myosin I beta

ALTERNATIVE UPACC:
O00159; Q4LE56; Q6NVJ7; Q86Y95

BACKGROUND:
The protein Unconventional myosin-Ic, with alternative name Myosin I beta, exhibits diverse functions including ATPase activity and involvement in intracellular movements. It plays a significant role in the recycling of glucose transporters in response to insulin, impacting the movement of intracellular GLUT4-containing vesicles. It is also a crucial component in the adaptation-motor complex of hair cells in the inner ear and contributes to the regulation of transcription by cooperating with the WICH chromatin-remodeling complex.

THERAPEUTIC SIGNIFICANCE:
Exploring the multifaceted functions of Unconventional myosin-Ic offers a promising avenue for the development of therapeutic strategies, especially in areas related to glucose metabolism and sensory cell mechanisms.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.